VVitenta
Medicines · Study29 September 2026·Verified source: New England Journal of Medicine, 29 September 2026 (Jastreboff et al., TRIUMPH-1), Eli Lilly, Reuters via FOX 9

Research moves forward: the main retatrutide trial is published

What changed

The TRIUMPH-1 trial was published in the New England Journal of Medicine: 2,339 adults with obesity and without diabetes, followed for 80 weeks. At the highest dose, average weight loss was 25.0%, compared with 3.9% on placebo. Retatrutide acts on three receptors (GLP-1, GIP and glucagon) and is given once a week.

What it means for you

  1. 1Retatrutide is not approved in any country. In the US, the maker gives early access only to a small number of patients who meet strict medical criteria, through their doctors. Products sold online as “retatrutide” are not approved medicines, and nobody can check what is in them.
  2. 2Good results come from the treatment you follow now, not the one you are waiting for. Questions about new options go to your doctor.

What the study does not show

The trial was funded by the maker and lasted 80 weeks. It did not compare retatrutide with Mounjaro or Wegovy and says nothing about people already on another treatment. In another trial from the same programme, 13.5% of participants on the highest dose stopped treatment because of side effects, compared with 4.8% on placebo.

What does not change

The approved medicines and their leaflets stay the same.

Sources

Is something missing on Vitenta?

Tell us what to add or what wasn't clear. Anonymous — no name, e-mail or phone.

What you write reaches only the team and is never shown on the site. Any content change is checked against the official leaflet.

Your suggestion
0/500 characters

Please don't include personal details.